Lipocine Inc.
LPCNHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframePart of the healthcare sector, Lipocine Inc. (LPCN) is listed under Biotechnology. With a market capitalization of $11.9M, it sits in micro-cap territory. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Market Cap
$11.9M
Beta
0.40
P/E (TTM)
—
P/E (Fwd)
-1.16
EPS (TTM)
$-1.82
EPS (Fwd)
$-1.24
ROE
-60.9%
ROA
-37.0%
Cash
$23.3M
Total Debt
$257,807
Free CF
-$6.9M
52W Change
-50.3%
Annual Financials
Cash vs Debt
Where LPCN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, LPCN finished 42.05% below its 150-day moving average ($2.64) and 63.83% below its 200-day moving average ($4.23). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LPCN overbought or oversold?
At the October 20, 2026 close, LPCN's RSI(14) was 22.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $23.3M in cash comfortably exceeding the $258K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$6.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -60.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $500K to $2.0M.
The relatively low beta of 0.40 suggests LPCN is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, LPCN has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing LPCN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.